UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

The lancet oncology, 2011-11, Vol.12 (12), p.1101-1108

2011

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

Journal of clinical oncology, 2024-09

2024

Volltextzugriff (PDF)

Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Breast cancer research and treatment, 2024-07, Vol.206 (1), p.207-207

2024

Volltextzugriff (PDF)

Concerns about cardiotoxicity in the HERA trial – Authors' reply

The Lancet (British edition), 2017-12, Vol.390 (10114), p.2767-2768

2017

Volltextzugriff (PDF)

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

Journal of clinical oncology, 2024-04, Vol.42 (11), p.1288-1300

2024

Volltextzugriff (PDF)

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

European journal of cancer (1990), 2021-05, Vol.148, p.287-296

2021

Volltextzugriff (PDF)

Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

Breast cancer research and treatment, 2021, Vol.185 (1), p.107-116

2021

Volltextzugriff (PDF)

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

Breast cancer research and treatment, 2022, Vol.191 (1), p.225-225

2022

Volltextzugriff (PDF)

Reply to L. Moscetti

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1628-1628

2017

Volltextzugriff (PDF)

Reply to A. Oguz et al

Journal of clinical oncology, 2016-02, Vol.34 (6), p.640-641

2016

Volltextzugriff (PDF)

Anastrozole and fulvestrant—combination to unlock efficacy

Nature reviews. Clinical oncology, 2012-10, Vol.9 (10), p.556-557

2012

Volltextzugriff (PDF)

Subpopulation Treatment Effect Pattern Plot (STEPP) Methods with R and Stata

Journal of Data Science, 2023-01, Vol.21 (1), p.106-126

2023

Volltextzugriff (PDF)

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

The Lancet (British edition), 2019-04, Vol.393 (10179), p.1440-1452

2019

Volltextzugriff (PDF)

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

The New England journal of medicine, 2015-01, Vol.372 (5), p.436-446

2015

Volltextzugriff (PDF)

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials

JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (16_suppl), p.508-508

2023

Volltextzugriff (PDF)

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO

Breast cancer research and treatment, 2019-08, Vol.177 (1), p.103

2019

Volltextzugriff (PDF)

A Quality-Adjusted Survival (Q-TWiST) Model for Evaluating Treatments for Advanced Stage Cancer

Journal of biopharmaceutical statistics, 2004-12, Vol.14 (1), p.111-124

2004

Volltextzugriff (PDF)

Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.GS2-04-GS2-04

2020

Volltextzugriff (PDF)

Reply to D. Serraino et al

Journal of clinical oncology, 2014-01, Vol.32 (2), p.161-161

2014

Volltextzugriff (PDF)

Abstract OT1-04-02: POSITIVE: A study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/big 8-13)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT1-04-02-OT1-04-02

2020

Volltextzugriff (PDF)

Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients’ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737–46

European urology, 2019-02, Vol.75 (2), p.e34-e35

2019

Volltextzugriff (PDF)

Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD3-01-PD3-01

2021

Volltextzugriff (PDF)

POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS596-TPS596

2018

Volltextzugriff (PDF)

Sex as a predictor of response to cancer immunotherapy – Authors' reply

The lancet oncology, 2018-08, Vol.19 (8), p.e380-e381

2018

Volltextzugriff (PDF)

1 – 25 von 279

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(267)
Mit Volltextzugriff
(152)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(278)
Russisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Concerns about cardiotoxicity in the HERA trial – Authors' reply

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

Reply to L. Moscetti

Reply to A. Oguz et al

Anastrozole and fulvestrant—combination to unlock efficacy

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Subpopulation Treatment Effect Pattern Plot (STEPP) Methods with R and Stata

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO

A Quality-Adjusted Survival (Q-TWiST) Model for Evaluating Treatments for Advanced Stage Cancer

Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Reply to D. Serraino et al

Abstract OT1-04-02: POSITIVE: A study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/big 8-13)

Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients’ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737–46

Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial

POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy

Sex as a predictor of response to cancer immunotherapy – Authors' reply

Aktive Filter

Suchergebnisse filtern